一家生物制药企业的日常，如何与亿万人的健康息息相关？早晨9点的实验室，正在发生什么？下午4点 的生产线，又如何运转？环球网独家纪实《智飞一日》，用镜头为您呈现智飞生物重庆、合肥、北京三 大研产基地，见证生物制药背后的科技创新与人性温度。镜头之下，是平凡的一天；镜头之外，是不平 凡的使命，致敬每一份为人类健康而努力的坚守。 来源：环球网 ...

证券日报网讯智飞生物9月19日在互动平台回答投资者提问时表示，公司深耕生物制药领域，聚焦主 业，通过"技术&市场"双轮驱动不断提升公司核心竞争力。公司持续优化经营策略以应对市场变化，促 进实现公司平稳发展。 （文章来源：证券日报） ...

（编辑 姚尧） 证券日报网讯 智飞生物9月19日在互动平台回答投资者提问时表示，公司打造了完善的科技创新平台体 系，形成智飞绿竹、智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局，不断强化公 司研发综合实力。截至目前，公司多款创新疫苗产品已进入申报上市及临床后期阶段：15价肺炎球菌结 合疫苗、ACYW135群流脑结合疫苗等四个产品处于上市审评阶段；福氏宋内氏痢疾双价结合疫苗、四 价重组诺如病毒疫苗等五个产品处于临床试验Ⅲ期。此外，公司治疗性生物制品在研管线的利拉鲁肽注 射液已位于申报上市阶段，司美格鲁肽注射液（降糖）已完成Ⅲ期临床试验，司美格鲁肽注射液（减 重）正位于Ⅲ期临床试验阶段。 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步提高上市公司投资者关系管理水平，促进公司完善公司治理，助力 上市公司高质量发展，重庆智飞生物制品股份有限公司（以下简称"公司"）将 参加由重庆证监局指导、重庆上市公司协会联合深圳市全景网络有限公司举办的 重庆辖区上市公司 2025 年投资者网上集体接待日暨半年度业绩说明会活动，现 将有关事项公告如下： 活动时间：2025 年 9 月 25 日（星期四）15:00-17:00。 登录网址：投资者可以登录全景网络平台（https://rs.p5w.net）进入本次 活动专区页面进行交流。 届时，公司高级管理人员将参加本次活动，通过网络在线交流形式，就公司 治理、发展战略、经营状况等投资者所关心的问题，与投资者进行沟通和交流。 证券代码：300122 证券简称：智飞生物 公告编号：2025-53 重庆智飞生物制品股份有限公司关于参加"重庆辖区上市公司2025年 投资者网上集体接待日暨半年度业绩说明会"的公告 衷心感谢投资者对公司的支持，欢迎广大投资者踊跃参与！ 特此公告 重庆智飞生物制品股份有限公司董事会 20 ...

中国经济网北京9月19日讯 智飞生物(300122.SZ)今日股价下跌，截至收盘报21.94元，跌幅 3.18%。 2021年5月17日，智飞生物股价创下历史最高点231.19元。 东方财富证券股份有限公司研究员何玮2021年4月29日发布研报《智飞生物(300122)2020年报点 评：自研代理双轮驱动 自研产品进入收获期》称，维持智飞生物"增持"评级。 （责任编辑：徐自立） ...

Core Viewpoint - The company emphasizes its commitment to AI in product development and has established a comprehensive technology innovation platform to enhance its R&D capabilities [1] Group 1: AI Investment and R&D - The company has built a strategic layout consisting of three major research and production bases and an innovation incubation center in Beijing [1] - Multiple innovative vaccine products are in various stages of regulatory approval and clinical trials, including the 15-valent pneumococcal conjugate vaccine and the ACYW135 group meningococcal conjugate vaccine [1] - The company is advancing therapeutic biological products, with liraglutide injection at the application stage and semaglutide injection (for diabetes) having completed phase III clinical trials [1]

Market Overview - On September 18, the biopharmaceutical sector declined by 0.38%, with Kanghua Biotech leading the drop [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Changchun High-tech: Closed at 130.31, up 5.19% with a trading volume of 233,800 shares and a turnover of 3.024 billion [1] - Zhifei Biological Products: Closed at 22.66, up 4.04% with a trading volume of 925,800 shares and a turnover of 2.12 billion [1] - ST Weiming: Closed at 8.88, up 3.26% with a trading volume of 182,300 shares and a turnover of 162 million [1] - Conversely, Kanghua Biotech experienced a significant decline, closing at 75.88, down 3.46% with a trading volume of 49,100 shares and a turnover of 381 million [2] Capital Flow - The biopharmaceutical sector saw a net inflow of 221 million from institutional investors, while retail investors experienced a net outflow of 340 million [2] - Key stocks with notable capital flows included: - Changchun High-tech: Net inflow of 353 million from institutional investors, with a net outflow of 283 million from retail investors [3] - Zhifei Biological Products: Net inflow of 10 million from institutional investors, with a net outflow of 125 million from retail investors [3] - Anke Bio: Net inflow of 64 million from institutional investors, with a net outflow of 877 million from retail investors [3]

Core Viewpoint - The stock price of Zhifei Biological surged over 6% following the announcement of clinical trial approval for its CA111 injection, a dual agonist targeting GIP and GLP-1 receptors, indicating potential growth in the obesity treatment market [1]. Group 1: Company Developments - Zhifei Biological's subsidiary, Chongqing Chen'an Biological Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults [1]. - CA111 injection is noted as a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with no other domestic products targeting the same receptors approved for market as of the announcement date [1]. Group 2: Market Impact - The approval of the clinical trial for CA111 injection is not expected to have a significant impact on the company's recent performance but is seen as beneficial for strengthening the company's research and development capabilities and pipeline reserves [1].

Core Insights - Chongqing Chanan Bio's CA111 injection has received clinical trial approval from the National Medical Products Administration, marking a significant step in its development for overweight or obese adults [1][3] - CA111 is a GIP/GLP-1 dual receptor agonist that works by stimulating insulin secretion and suppressing appetite, offering a complementary effect compared to single-target drugs [3] - The approval of CA111 highlights the company's focus on innovative technology and research, enhancing its product pipeline and providing more treatment options for domestic patients [3] Company Overview - CA111 is classified as a Class 1 innovative chemical drug with effective invention patents related to its molecular structure and use, targeting the high-demand areas of diabetes and weight loss [3] - Currently, only Eli Lilly's tirzepatide injection is approved in China as a GIP/GLP-1 dual receptor agonist, indicating a unique market position for Chanan Bio's product [3] - The clinical trial approval is a result of the company's commitment to innovation and research, which is expected to drive high-quality development and strengthen its integrated "prevention & treatment" strategy [3] Market Potential - The dual action of CA111 is anticipated to effectively reduce side effects associated with administration, enhancing its attractiveness in the competitive landscape of diabetes and obesity treatments [3] - The approval of CA111 is expected to enrich the company's research and development pipeline, providing a new impetus for growth and expanding treatment options for patients in China [3]

Group 1 - The core point of the article is that Zhifei Biological experienced a significant stock increase of 6.7% following the approval of its injection solution for clinical trials [1] Group 2 - The approval of the clinical trial is a positive development for the company, indicating progress in its product pipeline [1] - The market reaction reflects investor confidence in the company's future prospects following this regulatory milestone [1]